Advertise on podcast: The Lancet Haematology in conversation with

Thalassaemia care is advancing fast, from gene therapies to AI diagnostics, but access and prevention still lag behind. Hear from the authors of The Lancet Haematology's "Thalassaemia revisited: from health burden to breakthroughs" Series, produced with The Lancet Regional Health – Southeast Asia, on epidemiology across Asia, what's working in prevention, the real barriers to gene therapy access, and what's next for hydroxyurea, regional manufacturing, and AI in patient care. Click here to visit the series Hub page:  www.thelancet.com/series-do/thalassaemia Or read the full articles from: The Lancet Regional Heath Southeast Asia:  https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00148-4/fulltext and https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(26)00095-8/fulltext The Lancet Haematology: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00173-0/fulltext and https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00197-3/fulltext The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Blood cancer treatments are advancing fast — but so are their side effects. Hear from the authors of The Lancet Haematology's Adverse Event reporting series on better trial design, patient-centric care, and what part 2 (2026) reveals about long-term toxicity, survivorship, regulation, and digital health tools. Click here to visit the series hub on thelancet.com: https://www.thelancet.com/series-do/adverse-events-in-haematology-oncology The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Lan-Lan Smith joined the lead author of our latest Commission Dr Bethany Samuelson Bannow and author Dr Maureen Achebe to discuss classical haematological disease in women with Dr Julia Sandrin Gauer from the Intenational Society on Thrombosis and Haemostasis. The podcast was recorded and produced by the ISTH to coincide with the launch of the Commission at the ISTH congress in Paris in July 2026. Click here to read the commission on thelancet.com: https://www.thelancet.com/commissions-do/women-bleeding-thrombosis The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Most previous patient-reported outcome results for CAR T-cell therapy have come from clinical trials testing these treatments, but information on how patients experience this treatment in real-world settings is scarce. Dr Fabio Efficace and Dr Alice Di Rocco discuss their recent prospective study to measure real-world patient-reported symtomatic adverse events in those receiving CAR T-cell therapy for aggressive B-cell lymphomas, and how these outcomes match those reported by the physicans treating the patients. They discuss some of the rich and varied findings that they uncovered from their study. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00128-6/fulltext The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Carmelo Gurnari joins us to discuss the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee on diagnosis, prevention, treatment, and donor management of donor cell-derived haematological neoplasms after HCT click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00046-3/fulltext The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Penelope Stein joins us to discuss the development of new international guidelines for the diagnosis, management, and treatment of the rare, genetically-linked condition, acute prophyria. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00044-X/fulltext The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks. Click here to read the full articles: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext  https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00004-9/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext English version of this podcast: https://www.buzzsprout.com/1564352/episodes/18730659 Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Julio Delgado and Dr Valentín Ortiz-Maldonado join us to discuss the results of their phase 2 trial testing varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00328-X/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr Erica Kaye and Dr Dylan Graetz join us to discuss the importance of qualitative research and how the whole research ecosystem can incorporate and support this type of research to help set the right research questions, and promote the patient voice. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00321-7/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Professor Isabelle Mahé joins us to discuss the results of a post-hoc analysis of the API-CAT trial identifying predictors associated with clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00291-1/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Khaled Musallam, Bethany Samuelson Bannow, Mohamad Mohty, David Sallman, and Anna Sureda join us to share their expectations for the upcoming ASH 2025 congress, to be held from 6 to 9 December 2025 in Orlando, on classical and malignant haematology. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Professor Arnon Kater and Dr Sabina Kersting join us to discuss the results of their phase 2 trial testing a new first-line treatment regimen in chronic lymphocytic leukaemia: fixed-duration ibrutinib–venetoclax followed by MRD-guided ibrutinib–obinutuzumab intensification. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00288-1/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv

Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv The Lancet Haematology in conversation with...  is part of the Lancet Group podcast offering.  Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.  Find the best science for better lives at www.thelancet.com Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv